Literature DB >> 34161483

Limited cardiopulmonary capacity in patients with liver cirrhosis when compared to healthy subjects.

Igor Nasser1,2,3, Humberto Miranda1,2, Renata de Mello Perez4,5, Ramona Cabiddu6, Luciana Malosa7, Ingrid Dias1, Amanda Brown1, Michel Silva Reis1,4.   

Abstract

OBJECTIVES: The present study compared cardiorespiratory capacity between cirrhotic patients and healthy subjects.
METHODS: Nineteen cirrhotic patients and 19 healthy subjects, paired by age and gender, participated in the study. Volunteers performed an incremental cardiopulmonary test with a ramp protocol, a ventilatory and metabolic variables were obtained and analyzed. The recovery was analyzed by calculating the time needed for 50% of oxygen consumption (VO2) recovery to occur as the median between the peak of the exercise and the end of recovery on the VO2 curve (T1/2). The VE/VCO2 slope were performed by the linear regression of ventilation (VE) and carbon dioxide production (VCO2) data.
RESULTS: During resting condition, cirrhotic patients presented significantly higher levels of VO2 compared to healthy subjects. The VE/ VO2 and VE/ VCO2 values were significantly higher in the control group at the anaerobic threshold and at the peak of the test compared to cirrhotic patients. Time under effort was significantly higher for healthy subjects.
CONCLUSIONS: Based on these findings, it is possible to conclude that liver cirrhosis can compromise the patients' quality of life, mainly by inducing metabolic alterations which can impair functional capacity and lead to a sedentary lifestyle.

Entities:  

Mesh:

Year:  2021        PMID: 34161483     DOI: 10.1590/1806-9282.67.01.20200449

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  1 in total

1.  Six-minute walk test predicts future decompensation in patients with compensated liver cirrhosis.

Authors:  Diane Michela Nery Henrique; Carlos Alberto Mourao-Junior; Fabio Pace; Túlio Medina Dutra de Oliveira; Carla Malaguti; Julio Chebli
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-08       Impact factor: 1.712

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.